Mucosal Healing in Ulcerative Colitis - When Zero is Better

被引:84
作者
Carvalho, Pedro Boal [1 ]
de Castro, Francisca Dias [1 ]
Rosa, Bruno [1 ]
Moreira, Maria Joao [1 ]
Cotter, Jose [1 ,2 ,3 ]
机构
[1] Hosp Senhora Oliveira Guimaraes, Rua Cutileiros, P-4831044 Creixomil, Guimaraes, Portugal
[2] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Campus Gualtar, P-4710057 Braga, Portugal
[3] PT Govt Associate Lab, ICVS 3Bs, P-4710057 Guimaraes Braga, Portugal
关键词
Ulcerative colitis; mucosal healing; Mayo score; inflammatory bowel diseases; INFLAMMATORY-BOWEL-DISEASE; EVIDENCE-BASED CONSENSUS; ENDOSCOPIC ACTIVITY INDEXES; C-REACTIVE PROTEIN; FECAL CALPROTECTIN; PREDICTIVE FACTORS; CLINICAL-TRIALS; SEVERITY; RELAPSE; MANAGEMENT;
D O I
10.1093/ecco-jcc/jjv180
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and aims: Extensive evidence has underlined the importance of mucosal healing as a treatment aim for ulcerative colitis (UC). We aimed to assess differences in the incidence of clinical relapse at 12 months between UC patients with Mayo endoscopic scores (MES) 0 and 1. Methods: This retrospective study included consecutive patients in corticosteroid-free remission between 2008 and 2013 and with follow-up of at least 1 year, with MES 0 or 1 in complete colonoscopy. Clinical relapse was defined as need for induction treatment, treatment escalation, hospitalization or surgery. A p value < 0.05 was considered statistically significant. Results: The study included 138 patients, 72 (52.2%) female, with mean age of 49 (+/- 14) years. Inflammatory activity was classified as MES 0 in 61 (44.2%) patients and MES 1 in 77 (55.8%) patients. Clinical relapse during follow-up was significantly more frequent in patients with MES 1 than MES 0 (27.3 vs 11.5%, p = 0.022), and in the multivariate analysis MES 1 was the only factor significantly associated with an increased risk of relapse (odds ratio 2.89, 95% confidence interval 1.14-7.36, p = 0.026). This association was encountered in the subgroup of patients with left-sided/ extensive colitis (29.7 vs 11.1%, p = 0.049), but not proctitis (25.0 vs 12.0%, p = 0.202). Conclusions: In patients with UC in corticosteroid-free remission, particularly those with left-sided colitis or extensive colitis, MES 1 was significantly associated with a 3-fold increased risk of relapse compared with endoscopic MES 0. Our results support the use of endoscopic MES 0 as the most suitable treatment endpoint to define mucosal healing in patients with UC.
引用
收藏
页码:20 / 25
页数:6
相关论文
共 47 条
[1]   European evidence based consensus for endoscopy in inflammatory bowel disease [J].
Annese, Vito ;
Daperno, Marco ;
Rutter, Matthew D. ;
Amiot, Aurelien ;
Bossuyt, Peter ;
East, James ;
Ferrante, Marc ;
Goetz, Martin ;
Katsanos, Konstantinos H. ;
Kiesslich, Ralf ;
Ordas, Ingrid ;
Repici, Alessandro ;
Rosa, Bruno ;
Sebastian, Shaji ;
Kucharzik, Torsten ;
Eliakim, Rami .
JOURNAL OF CROHNS & COLITIS, 2013, 7 (12) :982-1018
[2]   Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis [J].
Ardizzone, Sandro ;
Cassinotti, Andrea ;
Duca, Piergiorgio ;
Mazzali, Cristina ;
Penati, Chiara ;
Manes, Gianpiero ;
Marmo, Riccardo ;
Massari, Alessandro ;
Molteni, Paola ;
Maconi, Giovanni ;
Porro, Gabriele Bianchi .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2011, 9 (06) :483-U117
[3]   Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation [J].
Baars, Judith E. ;
Nuij, Veerle J. A. A. ;
Oldenburg, Bas ;
Kuipers, Ernst J. ;
van der Woude, Christien J. .
INFLAMMATORY BOWEL DISEASES, 2012, 18 (09) :1634-1640
[4]   VARIATION BETWEEN OBSERVERS IN DESCRIBING MUCOSAL APPEARANCES IN PROCTOCOLITIS [J].
BARON, JH ;
CONNELL, AM ;
LENNARDJONES, JE .
BRITISH MEDICAL JOURNAL, 1964, 1 (5374) :89-+
[5]   Prognostic Value of Serologic and Histologic Markers on Clinical Relapse in Ulcerative Colitis Patients With Mucosal Healing [J].
Bessissow, Talat ;
Lemmens, Bart ;
Ferrante, Marc ;
Bisschops, Raf ;
Van Steen, Kristel ;
Geboes, Karel ;
Van Assche, Gert ;
Vermeire, Severine ;
Rutgeerts, Paul ;
De Hertogh, Gert .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 (11) :1684-1692
[6]   Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis [J].
Bitton, A ;
Peppercorn, MA ;
Antonioli, DA ;
Niles, JL ;
Shah, S ;
Bousvaros, A ;
Ransil, B ;
Wild, G ;
Cohen, A ;
Edwardes, MDD ;
Stevens, AC .
GASTROENTEROLOGY, 2001, 120 (01) :13-20
[7]   Predictive Factors of Response to Cyclosporine in Steroid-Refractory Ulcerative Colitis [J].
Cacheux, Wulfran ;
Seksik, Philippe ;
Lemann, Marc ;
Marteau, Philippe ;
Nion-Larmurier, Isabelle ;
Afchain, Pauline ;
Daniel, Fady ;
Beaugerie, Laurent ;
Cosnes, Jacques .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (03) :637-642
[8]  
Carbonnel F, 2000, ALIMENT PHARM THERAP, V14, P273
[9]   Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis [J].
Colombel, Jean Frederic ;
Rutgeerts, Paul ;
Reinisch, Walter ;
Esser, Dirk ;
Wang, Yanxin ;
Lang, Yinghua ;
Marano, Colleen W. ;
Strauss, Richard ;
Oddens, Bjoern J. ;
Feagan, Brian G. ;
Hanauer, Stephen B. ;
Lichtenstein, Gary R. ;
Present, Daniel ;
Sands, Bruce E. ;
Sandborn, William J. .
GASTROENTEROLOGY, 2011, 141 (04) :1194-1201
[10]   Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease [J].
Costa, F ;
Mumolo, MG ;
Ceccarelli, L ;
Bellini, M ;
Romano, MR ;
Sterpi, C ;
Ricchiuti, A ;
Marchi, S ;
Bottai, M .
GUT, 2005, 54 (03) :364-368